2752 Early-onset anaemia does not affect clinical activity of olaparib in advanced ovarian cancer patients: Pooled analysis of nine studies
Antoine Thiery-Vuillemin, Jane Robertson(Cancer Research UK), P.A. Galer-Frost, Emma McMurtry(AstraZeneca (United Kingdom))
Cited by 0
Related Papers
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
|British Journal of Cancer|2018|233